{"organizations": [], "uuid": "c641219352e08f95fbe12571d724d53fdade8648", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/deals", "section_title": "Deals News | Reuters", "url": "https://www.reuters.com/article/us-acaciapharma-ipo/britains-acacia-pharma-prices-brussels-stock-market-debut-idUSKCN1GE1IO", "country": "US", "domain_rank": 408, "title": "Britain's Acacia Pharma prices Brussels stock market debut", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.038, "site_type": "news", "published": "2018-03-02T19:40:00.000+02:00", "replies_count": 0, "uuid": "c641219352e08f95fbe12571d724d53fdade8648"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-acaciapharma-ipo/britains-acacia-pharma-prices-brussels-stock-market-debut-idUSKCN1GE1IO", "ord_in_thread": 0, "title": "Britain's Acacia Pharma prices Brussels stock market debut", "locations": [], "entities": {"persons": [{"name": "julian gilbert", "sentiment": "none"}, {"name": "gilbert", "sentiment": "none"}], "locations": [{"name": "brussels", "sentiment": "none"}, {"name": "brussels", "sentiment": "none"}, {"name": "britain", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "acacia pharma", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BRUSSELS (Reuters) - British group Acacia Pharma said on Friday it had priced its initial public offering on the Brussels stock exchange, raising 40 million euros ($49.09 million).\nThe company, which specializes in treatments of nausea and vomiting for post-operative and chemotherapy patients, said it would use the proceeds to prepare the launch of its first product.\n“Brussels really is an extremely good market for a company like ours,” Chief Executive Julian Gilbert told Reuters, adding that companies of a similar profile had performed well after listing there.\nThe group says it targets a potential market of some 16 million patients annually in the United States with BAREMSIS, its first product treating post-operative nausea, expected to be launched in 2019.\nWhile there are similar products, so-called dopamine antagonists, on the market already, the company said its product did not have safety issues associated with others.\n“We have found a safe dopamine antagonist, which gives us a unique position,” Gilbert said.“There is a big opportunity for us in rescue treatment.”\nAcacia Pharma is also carrying out phase 2 clinical trials for its next product aimed at chemotherapy patients.\nShares of the company, which will have a market capitalization of some 190 million euros, will start trading in Brussels on March 5.\nReporting by Robert-Jan Bartunek; Editing by Peter Graff\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-02T19:40:00.000+02:00", "crawled": "2018-03-02T19:56:20.114+02:00", "highlightTitle": ""}